BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:28 PM
 | 
Jul 23, 2008
 |  BC Extra  |  Top Story

Genzyme beats Street

Genzyme (NASDAQ:GENZ) reported 2Q08 non-GAAP diluted EPS of $0.98, beating by a penny the Street's estimate of $0.97 and up 11% from $0.88 in 2Q07. The company's 2Q08 revenues were $1.17 billion, up 25% from $933.4 million in 2Q07. The Street was expecting revenues of $1.13 billion.

Sales of Cerezyme imiglucerase for Type I Gaucher's disease were $319.4 million,...

Read the full 287 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >